Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

State-of-the-art Issues in Hodgkin’s Lymphoma Survivorship

State-of-the-art Issues in Hodgkin’s Lymphoma Survivorship The prognosis of Hodgkin’s lymphoma (HL) has markedly improved as management strategies evolved. In the modern era, less than 15% of patients with early-stage, non-bulky HL will relapse, and less than one third of those with advanced disease will relapse. As therapy for HL intensified, and as disease-related outcomes improved, the impact of the late effects of therapy has become increasingly important. There is a growing body of literature describing the late morbidity experienced by survivors of HL, including risks of second primary malignancy, cardiac disease, pulmonary disease, and endocrine dysfunction. Additionally, the impact of disease and treatment on psychosocial function and quality of life has been a subject of investigation, with survivors often suffering from impairment. An understanding of these risks and the management implications inherent to them is central to the care of survivors of HL. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Oncology Reports Springer Journals

State-of-the-art Issues in Hodgkin’s Lymphoma Survivorship

Current Oncology Reports , Volume 12 (6) – Aug 24, 2010

Loading next page...
 
/lp/springer-journals/state-of-the-art-issues-in-hodgkin-s-lymphoma-survivorship-UaRm8d1Oke

References (64)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology
ISSN
1523-3790
eISSN
1534-6269
DOI
10.1007/s11912-010-0123-2
pmid
20734173
Publisher site
See Article on Publisher Site

Abstract

The prognosis of Hodgkin’s lymphoma (HL) has markedly improved as management strategies evolved. In the modern era, less than 15% of patients with early-stage, non-bulky HL will relapse, and less than one third of those with advanced disease will relapse. As therapy for HL intensified, and as disease-related outcomes improved, the impact of the late effects of therapy has become increasingly important. There is a growing body of literature describing the late morbidity experienced by survivors of HL, including risks of second primary malignancy, cardiac disease, pulmonary disease, and endocrine dysfunction. Additionally, the impact of disease and treatment on psychosocial function and quality of life has been a subject of investigation, with survivors often suffering from impairment. An understanding of these risks and the management implications inherent to them is central to the care of survivors of HL.

Journal

Current Oncology ReportsSpringer Journals

Published: Aug 24, 2010

There are no references for this article.